Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025SEATTLE and VANCOUVER, British Columbia, Feb.…
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024…
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA…
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")…
Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LCLA), an…
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or…
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell,…
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds…